Reduction of Doxorubicin-Induced Cardiotoxicity Using
Nanocarriers: A Review

J 2017

Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ et. al.

Basic information

Original name

Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review

Authors

FOJTŮ, Michaela (203 Czech Republic, belonging to the institution), Jaromír GUMULEC (203 Czech Republic, belonging to the institution), Tibor STRAČINA (703 Slovakia, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Anna SKOTÁKOVÁ (203 Czech Republic, belonging to the institution), Markéta VACULOVIČOVÁ (203 Czech Republic), Vojtech ADAM (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Marie NOVÁKOVÁ (203 Czech Republic, belonging to the institution) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

Current Drug Metabolism, Sharjah, Bentham Science Publishers B.V. 2017, 1389-2002

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

United Arab Emirates

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.655

RIV identification code

RIV/00216224:14110/17:00097608

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.2174/1389200218666170105165444

UT WoS

000399610900006

Keywords in English

Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers

Abstract

V originále

Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. Objective: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicin-loaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. Conclusion: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.

Links

MUNI/A/1365/2015, interní kód MU

Name: Kardiovaskulární systém: od modelu přes terapii k prevenci (Acronym: KAMOTEPRE)

Investor: Masaryk University, Category A

Citovat

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ, Markéta VACULOVIČOVÁ, Vojtech ADAM, Petr BABULA, Marie NOVÁKOVÁ and Michal MASAŘÍK. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. Current Drug Metabolism. Sharjah: Bentham Science Publishers B.V., 2017, vol. 18, No 3, p. 237-263. ISSN 1389-2002. Available from: https://dx.doi.org/10.2174/1389200218666170105165444.

@article{1390003,
   author = {Fojtů, Michaela and Gumulec, Jaromír and Stračina, Tibor and Raudenská, Martina and Skotáková, Anna and Vaculovičová, Markéta and Adam, Vojtech and Babula, Petr and Nováková, Marie and Masařík, Michal},
   article_location = {Sharjah},
   article_number = {3},
   doi = {http://dx.doi.org/10.2174/1389200218666170105165444},
   keywords = {Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers},
   language = {eng},
   issn = {1389-2002},
   journal = {Current Drug Metabolism},
   title = {Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review},
   volume = {18},
   year = {2017}
}

TY  - JOUR
ID  - 1390003
AU  - Fojtů, Michaela - Gumulec, Jaromír - Stračina, Tibor - Raudenská, Martina - Skotáková, Anna - Vaculovičová, Markéta - Adam, Vojtech - Babula, Petr - Nováková, Marie - Masařík, Michal
PY  - 2017
TI  - Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
JF  - Current Drug Metabolism
VL  - 18
IS  - 3
SP  - 237-263
EP  - 237-263
PB  - Bentham Science Publishers B.V.
SN  - 13892002
KW  - Doxorubicin
KW  - nanoparticles
KW  - liposomal
KW  - polymeric
KW  - protein
KW  - gold
KW  - cardiotoxicity
KW  - nanocarriers
N2  - Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. Objective: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicin-loaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. Conclusion: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.
ER  -

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ, Markéta VACULOVIČOVÁ, Vojtech ADAM, Petr BABULA, Marie NOVÁKOVÁ and Michal MASAŘÍK. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. \textit{Current Drug Metabolism}. Sharjah: Bentham Science Publishers B.V., 2017, vol.~18, No~3, p.~237-263. ISSN~1389-2002. Available from: https://dx.doi.org/10.2174/1389200218666170105165444.

Detailed Information on Publication Record